» Articles » PMID: 2707301

Involvement of 5-HT Receptor Subtypes in the Discriminative Stimulus Properties of Mescaline

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 1989 Jan 2
PMID 2707301
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

In order to further evaluate the extent to which particular 5-HT receptor subtypes (5-HT1, 5-HT2) might be involved in the behavioral effects of hallucinogenic drugs, rats were trained to discriminate mescaline (10 mg/kg i.p.) from saline and were given substitution (generalization) and combination (antagonism) tests with putatively selective serotonergic and related neuroactive compounds. The mescaline cue generalized to relatively high doses of the 5-HT2 agonists, 2,5-dimethoxy-4-methylamphetamine (DOM), LSD and psilocybin; the extent of generalization to 5-HT1 agonists (8-hydroxy-2-[diethylamino]tetralin (8-OHDPAT), RU-24969 and 8-hydroxy-2-[di-n-propylamino]tetralin (TFMPP] was unclear. Combinations of the training drug and sufficiently high doses of 5-HT2 antagonists (ketanserin, LY-53857, pirenperone) were followed by saline-lever responding; less selective central 5-HT (metergoline), and DA (SCH-23390, haloperidol) antagonists, did not block the mescaline cue. These data suggest that 5-HT2 receptors are involved in the stimulus properties of mescaline.

Citing Articles

Transcriptomic Analysis of Glycosylation and Neuroregulatory Pathways in Rodent Models in Response to Psychedelic Molecules.

Oommen A, Roberts K, Joshi L, Cunningham S Int J Mol Sci. 2023; 24(2).

PMID: 36674723 PMC: 9867456. DOI: 10.3390/ijms24021200.


Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.

Kojic M, Saelens J, Kadriu B, Zarate Jr C, Kraus C Curr Top Behav Neurosci. 2022; 56:141-167.

PMID: 35312993 PMC: 10500612. DOI: 10.1007/7854_2022_313.


The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson M, Griffiths R, Hendricks P, Henningfield J Neuropharmacology. 2018; 142:143-166.

PMID: 29753748 PMC: 6791528. DOI: 10.1016/j.neuropharm.2018.05.012.


Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Halberstadt A Behav Brain Res. 2014; 277:99-120.

PMID: 25036425 PMC: 4642895. DOI: 10.1016/j.bbr.2014.07.016.


Determining the subjective and physiological effects of BZP combined with TFMPP in human males.

Lin J, Jan R, Lee H, Jensen M, Kydd R, Russell B Psychopharmacology (Berl). 2010; 214(3):761-8.

PMID: 21060995 DOI: 10.1007/s00213-010-2081-7.